S Diagbouga
Overview
Explore the profile of S Diagbouga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hien H, Meda N, Diagbouga S, Zoure E, Yameogo S, Tamboura H, et al.
Afr Health Sci
. 2013 Nov;
13(2):287-94.
PMID: 24235926
Background: There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future therapeutic strategies. Objectives: To...
2.
Godreuil S, Torrea G, Terru D, Chevenet F, Diagbouga S, Supply P, et al.
J Clin Microbiol
. 2007 Jan;
45(3):921-7.
PMID: 17251410
We conducted a molecular epidemiology study on 120 Mycobacterium tuberculosis isolates from patients presenting pulmonary tuberculosis (TB) in Burkina Faso. Classical antibiogram studies and genetic characterization, using mycobacterial interspersed repetitive-unit-variable-number...
3.
Vekemans M, Cartoux M, Diagbouga S, Dembele M, Kone B, Delafosse A, et al.
Clin Microbiol Infect
. 2002 Feb;
5(10):617-21.
PMID: 11851692
Objective: To identify potential sources of human Mycobacterium bovis infection in Bobo-Dioulasso, Burkina Faso. Methods: A tuberculin survey among 174 cattle was performed. Mycobacteriologic identification in 64 samples of pooled...
4.
Didier J, Kazatchkine M, Demouchy C, Moat C, Diagbouga S, Sepulveda C, et al.
J Acquir Immune Defic Syndr
. 2001 Mar;
26(2):193-5.
PMID: 11242190
No abstract available.
5.
Diagbouga S, Chiron J, Sanou O, Ledru E
Scand J Immunol
. 2001 Feb;
53(1):79-84.
PMID: 11169210
Peripheral CD4 T-cell depletion has been observed in human immunodeficiency virus (HIV)-negative patients with pulmonary tuberculosis (TB). To investigate more accurately this alteration, we studied peripheral blood CD45RA(+) and CD29(high)...
6.
Ouedraogo M, Ouedraogo S, Diagbouga S, Coulibaly G, Achi V, Domoua K, et al.
Rev Mal Respir
. 2000 Jun;
17(2):477-80.
PMID: 10859766
Percentages of primary and acquired resistance to anti-tuberculosis drugs provide an epidemiological indicator useful for assessing national anti-tuberculosis programs. Rifampicin and isoniazide are widely used in countries with a high...
7.
Diagbouga S, Durand G, Sanou P, Dahourou H, Ledru E
Trop Med Int Health
. 1999 Apr;
4(2):79-84.
PMID: 10206260
In the developed word, monitoring HIV-infected patients is routinely determined by CD4+ T lymphocyte absolute counts. The reference procedure, flow cytometry, is expensive, requires sophisticated instrumentation and operators with specific...
8.
Diagbouga S, Aldebert D, Fumoux F, Capron M, Ledru E
Scand J Immunol
. 1999 Mar;
49(2):203-9.
PMID: 10075026
Eosinophils are important effectors of the non-specific immune response and we studied whether perturbations in the production of the type 2 cytokine, interleukin-5 (IL-5), could account for the variations in...
9.
Anglaret X, Diagbouga S, Combe P, van de Perre P, Dabis F
Int J Epidemiol
. 1998 Dec;
27(5):928-9.
PMID: 9839756
No abstract available.
10.
Ledru E, Diagbouga S, Meda N, Sanou P, Dahourou H, Ledru S, et al.
Int J STD AIDS
. 1998 Aug;
9(8):463-70.
PMID: 9702595
Our objective was to propose a strategy to screen HIV-infected African people for biological immunodeficiency easily. In a cross-sectional study, we analysed the patterns of diseases and of CD4 counts...